Brain Study of Patients With Frontal Lobe Dementia and Parkinsonian Disorders - Full Text View

Sponsor:	National Institute of Neurological Disorders and Stroke (NINDS)
Information provided by:	National Institutes of Health Clinical Center (CC)
ClinicalTrials.gov Identifier:	NCT00001178

Purpose

The Cognitive Neuroscience Section of the National Institute of Neurological Disorders and Stroke proposes to continue its cross-sectional and longitudinal studies of cerebral metabolism in frontal lobe dementias and atypical basal ganglia disorders. These studies include repeated assessments of neuropsychological and brain anatomical and metabolic function in subjects with these important and possibly related brain disorders.

Condition
Alzheimer's Disease Dementia Down's Syndrome

Study Type:	Observational
Official Title:	Regional Cerebral Utilization of Glucose in Patients With a Diagnosis of Frontal Lobe Dementia, Atypical Parkinsonian Disorder, and Other Basal Ganglia Disorders

Resource links provided by NLM:

Genetics Home Reference related topics: 17q21.31 microdeletion syndrome Alzheimer disease Down syndrome familial paroxysmal nonkinesigenic dyskinesia Perry syndrome tetrasomy 18p

MedlinePlus related topics: Alzheimer's Disease Dementia Down Syndrome Neurologic Diseases

U.S. FDA Resources

Further study details as provided by National Institutes of Health Clinical Center (CC):

Enrollment:	597
Study Start Date:	January 1981

Detailed Description:

Objective

To continue the cross-sectional and longitudinal studies performed by the Cognitive Neuroscience Section of NINDS on the neuroanatomy, cerebral metabolism, neuropsychology, and genetics of frontotemporal dementia, corticobasal syndrome, and related brain disorders.

Study population

Frontal lobe dementias and atypical basal ganglia disorders including frontotemporal dementia, corticobasal syndrome, and related brain disorders.

Design

A cross-sectional assessment of neuropsychological, brain anatomical and metabolic function, and genetic measures in subjects with these disorders.

Outcome measures

MRI, FDG-PET, neuropsychological and clinical tests, genetics, and neuropathology.

Eligibility

Ages Eligible for Study:	18 Years and older
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	Yes

Criteria

Subjects will be recruited from the NIH referral center, neurological and psychiatric clinics, from self or family referral in response to advertisements or from private physicians. Healthy volunteers will include subjects who are considered at-risk for the development of FTD or CBS and subjects who serve as normal controls matched for key characteristics with the patients.

INCLUSION CRITERIA FOR PATIENTS:

Diagnosis of possible / probable FTD or CBS
Caregiver willing and able to accept the responsibilities involved in the study

EXCLUSION CRITERIA:

Pregnant women. Women of childbearing potential will be screened by history for the possibility of pregnancy and undergo a urine pregnancy test. These women will be excluded from the imaging portions of the protocol.
Behavioral symptoms that would preclude the gathering of data for the study
Other medical or social condition that would preclude participation in the opinion of the investigators

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00001178

Locations

United States, Maryland
National Institutes of Health Clinical Center, 9000 Rockville Pike
Bethesda, Maryland, United States, 20892

Sponsors and Collaborators

National Institute of Neurological Disorders and Stroke (NINDS)

More Information

Additional Information:

NIH Clinical Center Detailed Web Page This link exits the ClinicalTrials.gov site

Publications:

Schwartz M, Creasey H, Grady CL, DeLeo JM, Frederickson HA, Cutler NR, Rapoport SI. Computed tomographic analysis of brain morphometrics in 30 healthy men, aged 21 to 81 years. Ann Neurol. 1985 Feb;17(2):146-57.

Schlageter NL, Horwitz B, Creasey H, Carson R, Duara R, Berg GW, Rapoport SI. Relation of measured brain glucose utilisation and cerebral atrophy in man. J Neurol Neurosurg Psychiatry. 1987 Jun;50(6):779-85.

Duara R, Grady C, Haxby J, Ingvar D, Sokoloff L, Margolin RA, Manning RG, Cutler NR, Rapoport SI. Human brain glucose utilization and cognitive function in relation to age. Ann Neurol. 1984 Dec;16(6):703-13.

ClinicalTrials.gov Identifier:	NCT00001178 History of Changes
Other Study ID Numbers:	810010, 81-N-0010
Study First Received:	November 3, 1999
Last Updated:	January 6, 2012
Health Authority:	United States: Federal Government

Keywords provided by National Institutes of Health Clinical Center (CC):

Alzheimer's Disease
Cerebral Metabolism
Cerebrospinal Fluid
Dementia of the Alzheimer Type
18-F-Fluoro-2-Deoxy-D-Glucose (FDG)
Magnetic Resonance Imaging

Positron Emission Tomography
X-Ray Computed Tomography (CT)
Senile Dementia
Down Syndrome
Trisomy 21

Additional relevant MeSH terms:

Alzheimer Disease
Basal Ganglia Diseases
Dementia
Down Syndrome
Parkinsonian Disorders
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Tauopathies
Neurodegenerative Diseases

Delirium, Dementia, Amnestic, Cognitive Disorders
Mental Disorders
Mental Retardation
Neurobehavioral Manifestations
Neurologic Manifestations
Abnormalities, Multiple
Congenital Abnormalities
Chromosome Disorders
Genetic Diseases, Inborn
Movement Disorders

ClinicalTrials.gov processed this record on February 09, 2012